Genomenon and Amicus Therapeutics Partner to Advance Fabry Disease Awareness and Diagnosis Through Curation and Distribution of GLA Variant Evidence

Genomenon and Amicus Therapeutics have partnered to advance awareness, diagnosis, and research for Fabry disease. Genomenon curated and classified variants in the GLA gene using AI and expert review, making the variant evidence freely available through the Mastermind Genomic Intelligence Platform and submitted to ClinVar. The partnership aims to support faster diagnosis and more informed clinical decisions for patients and families affected by Fabry disease.